{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:35:39Z","timestamp":1792002939933,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","award":["13-115"],"award-info":[{"award-number":["13-115"]}],"id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jiac.2019.08.019","type":"journal-article","created":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T23:58:03Z","timestamp":1575849483000},"page":"236-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment"],"prefix":"10.1016","volume":"26","author":[{"given":"Kogenta","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Tobiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Kanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushu","family":"Onita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.08.019_bib1","series-title":"Flumarin (flomoxef for injection) prescribing information","author":"Shionogi","year":"2019"},{"key":"10.1016\/j.jiac.2019.08.019_bib2","first-page":"41","article-title":"Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia","volume":"69","author":"Partina","year":"2016","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2019.08.019_bib3","first-page":"378","article-title":"Antimicrobial activity of flomoxef against Enterobacteriaceae including extended spectrum beta-lactamases-producing strains isolated at Ramathibodi Hospital: a 1000-bed tertiary care hospital in Bangkok, Thailand","volume":"6","author":"Santanirand","year":"2018","journal-title":"J\u00a0Infect Dis Ther"},{"key":"10.1016\/j.jiac.2019.08.019_bib4","first-page":"71","article-title":"Evaluation of antibacterial activities of flomoxef against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation","volume":"66","author":"Ito","year":"2013","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2019.08.019_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.diagmicrobio.2018.11.017","article-title":"In\u00a0vitro activity of flomoxef against extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea","volume":"94","author":"Jung","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.019_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"The JAID\/JSC guidelines for clinical management of infectious disease 2015\u2014urinary tract infection\/male genital infection","volume":"23","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1442-2042.2007.01869.x","article-title":"Japanese guidelines for prevention of perioperative infections in urological field","volume":"14","author":"Matsumoto","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.jiac.2019.08.019_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12894-016-0169-z","article-title":"Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Urol"},{"issue":"Supplment 1","key":"10.1016\/j.jiac.2019.08.019_bib9","first-page":"968","article-title":"Diffusion into human prostate and clinical evaluation of 6315-S (flomoxef) in urinary tract infection","volume":"35","author":"Hoshi","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib10","first-page":"22","article-title":"A\u00a0clinical study on pulmonary tissue uptake of flomoxef","volume":"44","author":"Imaizumi","year":"1991","journal-title":"Jpn J Antibiot"},{"issue":"Supplment 1","key":"10.1016\/j.jiac.2019.08.019_bib11","first-page":"593","article-title":"Serum and sputum concentrations and clinical results of 6315-S (flomoxef) in respiratory tract infection","volume":"35","author":"Hayashi","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.jiac.2019.08.019_bib13","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Supplment 1","key":"10.1016\/j.jiac.2019.08.019_bib14","first-page":"137","article-title":"Assays of 6315-S (flomoxef) and its metabolites in body fluids by high-performance liquid chromatography","volume":"35","author":"Konaka","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A\u00a0pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J\u00a0Pharmacobio-Dyn"},{"key":"10.1016\/j.jiac.2019.08.019_bib16","first-page":"32","article-title":"Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation","volume":"24","author":"Nakamura","year":"2012","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","article-title":"Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation","volume":"41","author":"Nishikawa","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2019.08.019_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jiac.2017.08.005","article-title":"Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: dosing considerations for prostatitis","volume":"23","author":"Nakamura","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Progr Biomed"},{"key":"10.1016\/j.jiac.2019.08.019_bib21","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.44.8.2046-2051.2000","article-title":"A\u00a0population pharmacokinetic analysis of the penetration of the prostate by levofloxacin","volume":"44","author":"Drusano","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000329520","article-title":"Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination","volume":"57","author":"Bulitta","year":"2011","journal-title":"Chemotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.jiac.2019.08.019_bib23","first-page":"161","article-title":"Pharmacokinetic characterization of 6315-S (flomoxef) in experimental animals","volume":"35","author":"Kimura","year":"1987","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2019.08.019_bib24","first-page":"339","article-title":"Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents\u2014special references to bacteria isolated between April 2011 and March 2012","volume":"67","author":"Shinagawa","year":"2014","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2019.08.019_bib25","first-page":"73","article-title":"Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012","volume":"67","author":"Yamaguchi","year":"2014","journal-title":"Jpn J Antibiot"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19302697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19302697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:00:36Z","timestamp":1761159636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19302697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1341321X19302697"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.08.019","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}